ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener πŸ¦‹ Butterfly 8 Analysts πŸ›οΈ Policy 🎬 Video β˜… Watchlist 🎲 Prediction Markets πŸ“Š RQD Track Record πŸ“… Next Catalysts πŸ›‘οΈ Overlap & Crash X-Ray πŸ“° Live Wire πŸ‹ 13F Whales πŸ›οΈ Congress & CEO Buys πŸ† $100K Arena ⌘ Pro Terminal πŸ“ Methodology & Corrections
Stock Ratings / Health Care / AMPH / insiders
AVLN (44) RAPP (31) SPTX (55) MNKD (55) ⌘ Pro Terminal β†’

Amphastar Pharmaceuticals Inc. (AMPH) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$27.72 +2.93% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $27.93

Amphastar Pharmaceuticals Inc. (AMPH) earns a Roarable Rating of B (Buy) with 72/100 RQD Confidence. High-quality cash engine (50% profit margin, 9% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

πŸ“Š Historical Track Record: Scores of 72/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.0% avg 90D alpha vs SPY β€’ 68.7% hit rate) β†’
ROARABLE B β€’ BUY Cap $1.15B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on AMPH Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is AMPH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-02, Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $27.72 (+2.93% 1D, market cap $1.15B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, AMPH ranks #72 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does AMPH compare to AVLN and RAPP in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AMPH carries a Roarable B (72/100 RQD), trailing P/E of 11.7x, gross margin of 49.5%, and ROIC of 9.0%. By comparison, AVLN (Avalyn Pharma Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC β€”, cap $1.14B) and RAPP (Rapport Therapeutics Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -22.9%, cap $1.16B). Among the 5-stock peer group, AMPH leads on earnings multiple (11.7x) while MNKD leads on capital efficiency (54.5% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for AMPH?
β–Ό

Per AMPH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001297184), Amphastar Pharmaceuticals Inc. generated $719.9M in revenue (-1.7% YoY), $98.1M in net income, and $121.2M in free cash flow against $1.63B in total assets and $619.7M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $27.93 (+0.77%)🧬 Cannibal Buyback (-2.64% YoY Shares)βš™οΈ Cash Engine: 13/20 (C) β€’ 16.8% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record: Scores of 72/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.0% avg 90D alpha vs SPY β€’ 68.7% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERBUY β€’ B
025507510072
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B Β· Rk C+
Cash (13)Whales (15)SEC (11)Macro (16)CEO (17)
Each axis scored 0–20
12M PRICE TARGET CONE+6.3% Base Target
$35 Bull$29 Base$23 Bear
πŸ“¬ FREE AMPH RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for AMPH)Realized 20D OHLCV Swing Band: Β±6.9%
Deterministic 5-Pillar Attribution (72/100 Composite)
πŸ” WHY AMPH SCORES 72/100 (B) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Insider Conviction & Share Dilution+17/20 pts (24% of score)

SEC Form 4 / 13F Thermometer: 85% Net Buy β€’ Cannibal Buyback (-2.64% YoY Shares)

β–² #2 Bullish Driver: Macro Regime Fit+16/20 pts (22% of score)

FRED Regime Γ— Technicals: 86% of 52W Range β€’ RSI-14 at 58.9 (BULLISH MOMENTUM)

β–Ό #1 Drag / Risk Factor: SEC 10-K Forensic Risk11/20 pts (-9 pt drag)

Balance-sheet & 10-K footnote risk deducts 9 pts from forensic ceiling

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
64
Grade C+$26.76-2.3% Next Q
Q2 (-2Q)
67
Grade B-$26.14-2.6% Next Q
Q3 (-1Q)
69
Grade B-$25.47+8.8% Next Q
Current
72
Grade B$27.72+7% Hist 90D Ξ±
Trajectory: C+ (64) β†’ B (72)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

βš”οΈ Adversarial Opposing Case: Why the AMPH Bull Thesis Could Fail

Gideon Ashmere Forensic Desk β†’

Even with a 72/100 (B) score, AMPH faces multiple-compression risk if 11.7x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.64% YoY Shares) β€” any gross margin slip below 47.0% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($24.87) or 200D SMA ($22.25) invalidates the momentum regime and cuts Target Base ($29.47) toward Bear Floor ($22.73).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AMPHβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œAMPH Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 72%NO 28%Trade / Inspect Odds β†’
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

AMPH Smart-Money Thermometer: HEAVY INSIDER & 13F ACCUMULATION

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (AMPH)

No recent open-market Form 4 cluster sales or emergency dumps flagged on AMPH. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (AMPH Tape Review)

  • βœ“Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • βœ“Forensic Red-Light accounting & dilution traps to review on your watchlist
  • βœ“Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
AMPH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +21.90%β–² ASCENDING CHANNEL
2026-11-02O $26.33H $27.72L $26.33C $27.72VOL 371.4K
RES: $30.03SUP: $25.19SMA50: $24.87SMA200: $22.25
$28.58$25.35$22.11$18.88$15.65RES $30.03SUP $25.19$27.722026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AMPH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ AMPH Butterfly Map β†’ + Track AMPH β†’
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
2.0%/yr Implied 5Y Growth

vs. -1.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on AMPH today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for AMPH. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AMPH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AMPH)

Health Care Rank #72 of 1016 βš”οΈ AVLN vs AMPH Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (AMPH vs. AVLN, RAPP, SPTX, MNKD)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Amphastar Pharmaceuticals Inc. (AMPH) ranks #72 by composite RQD confidence (72/100, grade B) and #343 by equity capitalization ($1.15B). Within this direct 5-issuer industry benchmark cohort, AMPH leads on earnings valuation at 11.7x trailing P/E, while MNKD leads on capital efficiency and profitability with 54.5% ROIC and 92.3% gross margin. AMPH currently leads its immediate peer cohort in composite quantitative strength at 72/100 (B).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
AMPH ACTIVE
Amphastar Pharmaceuticals Inc.
B 72/100 11.7x 49.5% 9.0% +2.93% $1.15B Benchmark Subject
AVLN
Avalyn Pharma Inc.
D 44/100 β€” β€” β€” -0.31% $1.14B /avln-vs-amph β†’
RAPP
Rapport Therapeutics Inc.
E 31/100 β€” β€” -22.9% +3.47% $1.16B /rapp-vs-amph β†’
SPTX
Seaport Therapeutics Inc.
D+ 55/100 β€” β€” β€” -7.11% $1.13B /sptx-vs-amph β†’
MNKD
MannKind Corporation
D+ 55/100 β€” 92.3% 54.5% 0.00% $1.13B /mnkd-vs-amph β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001297184

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Amphastar Pharmaceuticals Inc. (AMPH) reported GAAP revenue of $719.9M (-1.7% vs. FY2024 revenue of $732.0M , and +11.7% cumulative change since FY2023) , GAAP net income of $98.1M, operating cash flow of $156.1M, and free cash flow of $121.2M (-29.7% YoY). On the balance sheet, AMPH closed FY2025 with $1.63B in total assets against $619.7M in total debt (Altman Z-Score: 2.47, Piotroski F-Score: 7/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $719.9M $98.1M $156.1M $121.2M $1.63B $619.7M
FY2024 (FY) 2024-12-31 $732.0M $159.5M $213.4M $172.3M $1.58B $613.5M
FY2023 (FY) 2023-12-31 $644.4M $137.5M $183.5M $183.5M β€” β€”

3. AMPH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AMPH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $27.72 (+2.93% 1D, market cap $1.15B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, AMPH ranks #72 in composite RQD confidence.

How does AMPH compare to AVLN and RAPP in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AMPH carries a Roarable B (72/100 RQD), trailing P/E of 11.7x, gross margin of 49.5%, and ROIC of 9.0%. By comparison, AVLN (Avalyn Pharma Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC β€”, cap $1.14B) and RAPP (Rapport Therapeutics Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -22.9%, cap $1.16B). Among the 5-stock peer group, AMPH leads on earnings multiple (11.7x) while MNKD leads on capital efficiency (54.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for AMPH?

Per AMPH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001297184), Amphastar Pharmaceuticals Inc. generated $719.9M in revenue (-1.7% YoY), $98.1M in net income, and $121.2M in free cash flow against $1.63B in total assets and $619.7M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is AMPH trading relative to its 50-day, 200-day, and 52-week technical levels?

AMPH last traded at $27.72 (+2.93% on volume of 664,538 shares), positioning the stock +11.46% above its 50-day simple moving average ($24.87) and +24.58% above its 200-day simple moving average ($22.25). Across its 52-week range of $16.65 to $29.52, AMPH sits at the 86.0% percentile with a 14-day RSI of 58.9 (BULLISH MOMENTUM) and an implied next-earnings move of Β±6.9% ($25.81 to $29.63).

AMPH Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS β€’ SEC EDGAR Γ— CBOE Γ— FRED

Are AMPH insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies AMPH leadership and institutional positioning as: HEAVY INSIDER & 13F ACCUMULATION.

Direct Sub-Reports: AMPH RQD Cockpit AMPH 12M Forecast AMPH Earnings & Move AMPH Dividends & DRIP AMPH Insiders & 13F AMPH Whale Options AMPH Profit Sankey AMPH News & Why
ROARABLE RATING BRIEF β€’ RQD 72/100 (B) βœ“ STAGE-C NUMBER FIREWALL VERIFIED

AMPH β€” Amphastar Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:30:32Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, AMPH scores 72 out of 100, earning a letter grade of B and the verdict label "Roarable Buy β€” Good Risk/Reward." The five pillars are:

  • Fundamental Cash Engine: 13 / 20. Per the Roarable RQD rating, this pillar reflects ROIC of 9% and an FCF yield of 10.58%. Cash generation is a relative strength, but the ROIC figure is modest, which limits how much the company earns on invested capital.
  • Whale 13F Flow: 15 / 20. Per the Roarable RQD rating, this pillar reflects institutional accumulation and options positioning. The source data contains no 13F holdings detail, so the basis for this score cannot be traced further in the source data.
  • Insider Conviction: 17 / 20. Per the Roarable RQD rating, this is the highest-scoring pillar and reflects SEC Form 4 and Congressional PTR cluster flow. The underlying transactions are not itemized in the source data.
  • Macro Regime Fit: 16 / 20. Per the Roarable RQD rating, this pillar reflects a Beta of 1.0 and sector sensitivity, implying market-level volatility relative to the broader market.
  • Forensic Balance Sheet: 11 / 20. Per the Roarable RQD rating, this pillar reflects an Altman Z-Score of 2.47, a Piotroski F-Score of 7/9, and a Debt/Equity ratio of 0.79. This is the lowest-scoring pillar and the main area of caution.

For a prospective investor, the rating points to a stock with solid cash generation and strong insider-flow signals, offset by a balance sheet that scores lower than the other pillars. Per the Roarable RQD rating, the investment case rests on whether cash generation can sustain debt service, and on how the stock's valuation (P/E TTM 11.7, Forward P/E 10.9) reflects that balance. A low multiple paired with a 10.58% FCF yield may indicate upside if cash flow holds, but it also reflects the market's assessment of risks that the source data does not fully explain. This is an analytical summary, not personalized advice.

Snapshot

PriceMarket CapP/E (TTM)Forward P/EEV/EBITDAEPS (TTM)Dividend YieldBeta52-Wk RangeROIC %
26.93$1.15B11.710.99.42.310%1.0$16.65 - $29.529%

Business

Per the company profile, Amphastar Pharmaceuticals Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Pharmaceutical Preparations. Per the profile, its market capitalization is $1.1B. Per the market data, gross margin is 49.5%, operating margin 19.5%, and net margin 13.6%. Not available in source data for: specific product lines, customer segments, or the detailed revenue model.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$719.9M$140.4M$98.1MN/A$121.2M$170.2M$619.7M
FY 2024$732.0M$205.4M$159.5MN/A$172.3M$151.6M$613.5M
FY 2023$644.4M$197.0M$137.5MN/A$183.5MN/AN/A

Per the SEC financials, revenue declined from $732.0M in FY 2024 to $719.9M in FY 2025, while net income fell from $159.5M to $98.1M and FCF from $172.3M to $121.2M. Per the market data, ROIC is 9%. Per the Roarable RQD rating, the Altman Z-Score is 2.47 and the Piotroski F-Score is 7/9. Per the Roarable RQD rating, Debt/Equity is 0.79. Debt rose from $613.5M to $619.7M while cash increased from $151.6M to $170.2M over the same period.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts feed, all items relate to AMPH and are headline-level coverage from aggregators (Yahoo! Finance Canada, Yahoo Finance UK, Yahoo Finance, MarketBeat, The Globe and Mail, and StockStory). Several are generic market-positioning pieces. The most notable items are:

  • A MarketBeat report stating the stock is "Reduce" rated by Wall Street analysts (marked as market wire).
  • A StockStory item titled "3 value stocks that fall short," flagged as RISK WATCH (red light).
  • A Globe and Mail piece framing AMPH among "Safe-and-Steady" and "Facing Challenges" candidates.

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. The news feed does not identify specific product, regulatory, or earnings catalysts; the item contents beyond headlines are not available in source data.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is NONE, with no upstream or downstream links and no proprietary signals recorded. Therefore, upstream and downstream dependencies, sector correlations, and 2nd-order bottlenecks are not available in source data. A prospective investor should note that the absence of mapped links means no supply-chain ripple analysis is supported by this dataset.

Open Questions

  • What drove the decline in revenue, net income, and FCF from FY 2024 to FY 2025, and is the trend continuing into the current period?
  • Which specific product lines and customers generate revenue, and how concentrated is that revenue?
  • What are the terms, maturities, and interest costs of the $619.7M in debt, and how does the company plan to service it?
  • Who are the insiders and institutions behind the cited Form 4 and 13F flows, and what sizes and timing do those transactions show?
  • What is the basis for the "Reduce" consensus rating referenced in the news feed, and does it conflict with the RQD verdict?

AMPH Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Amphastar Pharmaceuticals Inc. (AMPH) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to AMPH Debate Forum (3) ↓
🟑 MARKET WIRE Yahoo β€’ 3d ago
3 profitable stocks with warning signs

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

Read Full Source β†—
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

AMPH Bull vs. Bear Conversation Board β€” What's Your Call at $27.72?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AMPH 🐻 33% BEARISH CONVICTION
1. Pick Your Side on AMPH:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk πŸ‚ BULLISH 🎯 Target: $31.78 (+18.0%)
πŸ“Œ Pinned Debate

πŸ”₯ Official Bull vs. Bear Debate: Is AMPH (B β€’ RQD 72/100) a Buy at $26.93?

Welcome to the AMPH (Amphastar Pharmaceuticals Inc.) Roar Pit. Current RQD Composite is 72/100 (Roarable Buy β€” Good Risk/Reward) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (πŸ‚ Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $21.81 (-19.0%)
Spot @ $26.93

Pump the brakes on AMPH β€” check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on AMPH, but look at what you are paying: 11.7x trailing P/E with 49.5% gross margins. Unless Amphastar Pharmaceuticals Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

AL AlphaFlow_Cap Verified K Arena Trader πŸ‚ BULLISH 🎯 Target: $34.20 (+27.0%)
Spot @ $26.93

AMPH cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on AMPH, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $26.93 (52-wk range $16.65 - $29.52), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%